Download PDF
Zeitschrift für Ganzheitliche Tiermedizin 2014; 28(1): 19-29
DOI: 10.1055/s-0033-1360206
Ganzheitlicher Exkurs
Sonntag Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG Stuttgart · New York

Biologische Behandlung als Therapieoption bei equinem Cushing-Syndrom

Therapieansätze und Fallbeispiele aus der PraxisBiological treatment as therapy option for equine Cushingʼs syndrome: Therapy methods and case studies from veterinary practice
Tina Wassing
Further Information

Publication History

Publication Date:
18 February 2014 (online)

    Permissions and Reprints All articles of this category

Zusammenfassung

Mit zunehmendem Alter erkranken Pferde häufig am equinen Cushing-Syndrom (ECS). Als Therapie werden konventionell in der Regel Pergolid-Präparate eingesetzt. Adjuvant oder als alleinige Therapie bietet sich eine biologische Behandlung an, die als Basistherapie Hypophysis suis-Injeel oder Glandula suprarenalis-Injeel je nach Ernährungszustand einsetzt, dazu als Katalysator-Präparat Coenzyme compositum bzw. Ubichinon compositum. Zusätzlich werden weitere 1–2 Präparate je nach vorherrschenden Symptomen des individuellen Falles angewandt, um die individuelle Symptomatik möglichst gut abzudecken. Anhand von 3 Fallbeispielen wird die Wirkung dieser biologischen Behandlung als alleinige oder adjuvante Therapie aufgezeigt.

Summary

With increasing age, horses often suffer from equine Cushingʼs syndrome. Conventionally, pergolide products are typically used as therapy. Biological treatment can be used as adjuvant or sole therapy by applying basic therapy of Hypophysis suis-Injeel or Glandula suprarenalis-Injeel, (depending on nutritional status) as well as the catalyst preparation Co-enzyme compositum or Ubiquinone compositum. In addition, 1–2 further preparations are applied depending on the predominant symptoms of the individual case by bearing in mind the individual symptoms as well. With the use of three case studies, the article discusses the effect of biological treatment either as sole or adjuvant therapy.

Key words

Cushingʼs disease - horse - biological treatment
 

  • Literatur

  • 1 Aleman M, Watson JL, Williams DC et al. Myopathy in horses with pituitary pars intermedia dysfunction (Cushingʼs disease). Neuromuscul Disord 2006; 16: 737-744
    CrossrefGoogle Scholar
  • 2 Beech J, Boston RC, McFarlane D et al. Evaluation of plasma ACTH, alpha-melanocyte-stimulating hormone, and insulin concentrations during various photoperiods in clinically normal horses and ponies and those with pituitary pars intermedia dysfunction. J Am Vet Med Assoc 2009; 235: 715-722
    CrossrefGoogle Scholar
  • 3 Bradaric Z. Untersuchung zum Equinen Cushing Syndrom und Prüfung der Wirksamkeit von Vitex agnus-castus (Mönchspfeffer) bei der Behandlung des Equinen Cushing Syndroms. [Diss. med. vet.]. Berlin: 2012
    Google Scholar
  • 4 Brosnahan MM, Paradis MR. Assessment of clinical characteristics, management practices, and activities of geriatric horses. J Am Vet Med Assoc 2003; 223: 99-103
    CrossrefGoogle Scholar
  • 5 Carter RA, Geor RJ, Burton Staniar W et al. Apparent adiposity assessed by standardised scoring systems and morphometric measurements in horses and ponies. Vet J 2009; 179: 204-210
    CrossrefGoogle Scholar
  • 6 de Laat MA, Kyaw-Tanner MT, Sillence MN et al. Advanced glycation endproducts in horses with insulin-induced laminitis. Vet Immunol Immunopathol 2012; 145: 395-401
    CrossrefGoogle Scholar
  • 7 Donaldson MT, LaMonte BH, Morresey P et al. Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushingʼs disease). J Vet Intern Med 2002; 16: 742-746
    Google Scholar
  • 8 Frank N, Andrews FM, Sommardahl CS et al. Evaluation of the combined dexamethasone suppression/thyrotropin-releasing hormone stimulation test for detection of pars intermedia pituitary adenomas in horses. J Vet Intern Med 2006; 20: 987-993
    CrossrefGoogle Scholar
  • 9 Frank N, Geor RJ, Bailey SR et al. Equine metabolic syndrome. J Vet Intern Med 2010; 24: 467-475
    CrossrefGoogle Scholar
  • 10 Froin HR. Das equine Cushing-Syndrom. Pathophysiologie und Diagnostik der hypophysären Dysfunktion der Pars intermedia. BPT-Kongress, 9.–12. 10. 1997, Münster. 1997.
    Google Scholar
  • 11 Glover CM, Miller LM, Dybdal NO. Extrapituitary and pituitary pathological findings in horses with pituitary pars intermedia dysfunction: A retrospective study. J Equine Vet Sci 2009; 29: 146-153
    CrossrefGoogle Scholar
  • 12 Grenager N. How does Cushingʼs disease relate to laminitis? Advances in diagnosis and treatment. J Equine Vet Sci 2010; 30: 482-490
    CrossrefGoogle Scholar
  • 13 Iwen KA, Senyaman O, Schwartz A et al. Melanocortin crosstalk with adipose functions: ACTH directly induces insulin resistance, promotes a pro-inflammatory adipokine profile and stimulates UCP-1 in adipocytes. J Endocrinol 2008; 196: 465-472
    CrossrefGoogle Scholar
  • 14 Johnson PJ, Messer NT, Ganjam VK. Cushingʼs syndromes, insulin resistance and endocrinopathic laminitis. Equine Vet J 2004; 36: 194-198
    Google Scholar
  • 15 Klammer S. Einfluss von POMC-Derivaten auf die Nebenniere. [Diss. med.]. Freiburg: 2007
    Google Scholar
  • 16 Lee ZY, Zylstra R, Haritou SJ. The use of adrenocorticotrophic hormone as a potential biomarker of pituitary pars intermedia dysfunction in horses. Vet J 2010; 185: 58-61
    CrossrefGoogle Scholar
  • 17 McFarlane D. Advantages and limitations of the equine disease, pituitary pars intermedia dysfunction as a model of spontaneous dopaminergic neurodegenerative disease. Ageing Res Rev 2007; 6: 54-63
    CrossrefGoogle Scholar
  • 18 McFarlane D. Equine pituitary pars intermedia dysfunction. Vet Clin North Am Equine Pract 2011; 27: 93-113
    CrossrefGoogle Scholar
  • 19 McFarlane D, Dybdal N, Donaldson MT et al. Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction. J Neuroendocrinol 2005; a 17: 73-80
    CrossrefGoogle Scholar
  • 20 McFarlane D, Miller LM, Craig LE et al. Agreement in histologic assessments of the pituitary pars intermedia in aged horses. Am J Vet Res 2005; b 66: 2055-2059
    CrossrefGoogle Scholar
  • 21 McGowan CM. Endocrine disorders in the geriatric horse. Proc 48th BEVA, 9. – 12.9.2009, Birmingham/England. 2009.
    Google Scholar
  • 22 McGowan CM, Frost R, Pfeiffer DU et al. Serum insulin concentrations in horses with equine Cushingʼs syndrome: response to a cortisol inhibitor and prognostic value. Equine Vet J 2004; 36: 295-298
    Google Scholar
  • 23 McGowan TW, Hodgson DR, McGowan CM. The prevalence of equine Cushingʼs syndrome in aged horses. J Vet Intern Med 2007; 21: Abstract 113
    Google Scholar
  • 24 Perkins GA, Lamb S, Erb HN, et al. Nydam DV Divers TJ. Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushingʼs disease with cyproheptadine or pergolide. Equine Vet J 2002; 34: 679-685
    Google Scholar
  • 25 Potenza MA, Marasciulo FL, Chieppa DM et al. Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am J Physiol Heart Circ Physiol 2005; 289: H813-822
    CrossrefGoogle Scholar
  • 26 Schott HC. Diagnosis and treatment of equine Cushingʼs disease. Proc 17th Congress IAEV, 4. – 6.2.2011, Montesilvano/Italien. 2011.
    Google Scholar
  • 27 Schott HC. Pituitary pars intermedia dysfunction: equine Cushingʼs disease. Vet Clin North Am Equine Pract 2002; 18: 237-270
    CrossrefPubMedGoogle Scholar
  • 28 Sgorbini M, Panzani D, Maccheroni M et al. Equine cushing-like syndrome: diagnosis and therapy in two cases. Vet Res Commun 2004; 28 (Suppl. 01) 377-380
    CrossrefGoogle Scholar
  • 29 Treiber KH, Kronfeld DS, Geor RJ. Insulin resistance in equids: possible role in laminitis. J Nutr 2006; 136: 2094S-2098S
    Google Scholar
  • 30 van der Kolk JH. Equine Cushingʼs disease. Equine Vet Education 1997; 9: 209-214
    Google Scholar
  • 31 Walsh DM, McGowan CM, McGowan TW et al. Correlation of plasma insulin concentration with laminitis score in a field study of equine Cushingʼs disease and equine metabolic syndrome. J Equine Vet Sci 2009; 29: 87-94
    CrossrefGoogle Scholar